Fetal neurobehavioral effects of exposure to methadone or buprenorphine

Lauren M. Jansson, Janet A. DiPietro, Martha Velez, Andrea Elko, Erica Williams, Lorraine Milio, Kevin O'Grady, Hendrée E. Jones

Research output: Contribution to journalArticlepeer-review


As part of a double-blind study of medication treatment for opioid dependence during pregnancy, 17 opioid-dependent pregnant women maintained on either buprenorphine or methadone underwent fetal monitoring at 24, 28, 32, and 36. weeks gestation. Maternal demographic information and infant outcomes did not significantly differ by medication group. Earlier in gestation (24 and 28. weeks), buprenorphine-exposed fetuses had higher levels of fetal heart rate variability, more accelerations in fetal heart rate and greater coupling between fetal heart rate and fetal movement than the methadone-exposed group (all ps < .05). Later in gestation (32 and 36. weeks), buprenorphine-exposed fetuses displayed less suppression of motor activity and longer duration of movements than the methadone-exposed group (all ps < .05). These results may have implications for the optimal treatment of the opioid-dependent pregnant woman.

Original languageEnglish (US)
Pages (from-to)240-243
Number of pages4
JournalNeurotoxicology and Teratology
Issue number2
StatePublished - Mar 2011


  • Buprenorphine
  • Drug dependency
  • Fetus
  • Methadone
  • Opioids
  • Pregnancy

ASJC Scopus subject areas

  • Toxicology
  • Developmental Neuroscience
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'Fetal neurobehavioral effects of exposure to methadone or buprenorphine'. Together they form a unique fingerprint.

Cite this